Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
Rhea-AI Summary
Telix (ASX: TLX, NASDAQ: TLX) will host an educational webinar on PSMA-targeted radionuclide therapy, focusing on Telix’s multi-product approach to prostate cancer. Speakers: Dr. David N. Cade and Professor Louise Emmett. Topic: OPTIMAL-PSMA2 data on TLX597-Tx (177Lu-DOTA-PSMA).
Webinar: AEST Thursday April 30, 2026 9:30 a.m.; EDT Wednesday April 29, 2026 7:30 p.m. Registration link available. TLX597-Tx has not received marketing authorization in any jurisdiction.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – TLX
On the day this news was published, TLX gained 0.38%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TLX slipped 1.52% with light volume while key biotech peers were mixed: RARE (-0.66%), APLS (+0.02%), LGND (+0.57%), MLTX (-2.32%), ZLAB (-1.04%). Momentum scanners only flagged ADMA (+2.47%), suggesting today’s action is stock-specific rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 21 | ASCO Phase 3 data | Positive | +1.2% | Late-breaking ASCO 2026 presentation for ProstACT Global Phase 3 safety data. |
| Apr 14 | Phase 3 trial start | Positive | -0.4% | First patient dosed in pivotal Phase 3 IPAX BrIGHT glioblastoma trial. |
| Apr 13 | Strategic collaboration | Positive | +6.6% | Regeneron radiopharma collaboration with US$40M upfront and up to US$2.1B milestones. |
| Apr 09 | NDA acceptance | Positive | +7.5% | FDA acceptance of resubmitted NDA for TLX101-Px with PDUFA date set. |
| Apr 08 | Board appointments | Positive | +0.2% | Two Non-Executive Directors appointed to strengthen governance and expertise. |
Recent substantive clinical and regulatory milestones have often seen positive price alignment, with one notable divergence on a Phase 3 trial start.
Over recent months, Telix has reported multiple clinical and strategic milestones. These include Phase 3 activity in glioblastoma, late-breaking ASCO data for its ProstACT study, a strategic radiopharma collaboration with Regeneron featuring US$40 million upfront and up to US$2.1 billion in milestones, an FDA-accepted NDA for TLX101-Px with a September 11, 2026 PDUFA date, and new board appointments effective May 11, 2026. The current educational PSMA webinar fits a pattern of ongoing engagement around Telix’s radiopharmaceutical pipeline.
Market Pulse Summary
This announcement highlights Telix’s efforts to educate clinicians and investors on PSMA-targeted radionuclide therapy and its second-generation candidate TLX597-Tx, which currently lacks marketing authorization. It fits alongside recent milestones such as the ProstACT Phase 3 update, the Regeneron collaboration with up to US$2.1 billion in milestones, and the TLX101-Px PDUFA date of September 11, 2026. Observers may watch for formal trial readouts or regulatory decisions as clearer catalysts than an educational event.
Key Terms
psma medical
radionuclide therapy medical
theranostics medical
investigator-initiated trial medical
marketing authorization regulatory
AI-generated analysis. Not financial advice.
MELBOURNE, Australia and INDIANAPOLIS, April 28, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) announces an educational webinar exploring the evolution of PSMA1-targeted radionuclide therapy and Telix’s differentiated, multi-product approach to treating prostate cancer across the disease continuum.
Dr. David N. Cade, Telix Group Chief Medical Officer will host a discussion with Professor Louise Emmett, Director of Theranostics and Nuclear Medicine at St Vincent’s Hospital in Sydney, exploring what makes an effective PSMA-targeted therapy.
Professor Emmett will showcase data from her OPTIMAL-PSMA2 investigator-initiated trial of TLX597-Tx (177Lu-DOTA-PSMA), Telix’s novel second generation small molecule candidate being developed to facilitate patient access to lutetium therapy in select geographies.
The presentation will be followed by Q&A.
Webinar date and time:
AEST: Thursday April 30, 2026, 9:30 a.m.
EDT: Wednesday April 29, 2026, 7:30 p.m.
Participants can register for the webinar at the following link:
https://s1.c-conf.com/diamondpass/10053985-675tre.html
TLX597-Tx has not received a marketing authorization in any jurisdiction.
About Telix Pharmaceuticals Limited
Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
| Telix Investor Relations (Global) | Telix Investor Relations (Australia) | Telix Investor Relations (U.S.) |
| Ms. Kyahn Williamson | Ms. Charlene Jaw | Ms. Annie Kasparian |
| SVP Investor Relations and Corporate Communications | Associate Director Investor Relations | Director Investor Relations and Corporate Communications |
| kyahn.williamson@telixpharma.com | charlene.jaw@telixpharma.com | annie.kasparian@telixpharma.com |
This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.
Legal Notices
Cautionary Statement Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.
©2026 Telix Pharmaceuticals Limited. All rights reserved.
1 Prostate-specific membrane antigen.
2 Australian New Zealand Clinical Trials Registry ID: ACTRN12625000971437.
